Michael J. Fox Foundation for Parkinson's Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD research to prioritize research toward transformative treatments and a cure for Parkinson's disease (PD).

The Edmond J. Safra Core Programs include the Rapid Response Innovation Awards, focused on breakthrough ideas; Target Validation, which supports testing of biological targets with potential to become the new PD drugs of the future; and the Therapeutic Pipeline Program, designed to support critical preclinical and clinical development of Parkinson's therapies.

"The Edmond J. Safra Core Programs for PD Research provide consistent, significant funding for investigator-initiated projects that can help us achieve our goal sooner rather than later," said Todd Sherer, Ph.D., chief executive of MJFF.